Our Story

Immediately,

accurately,

with no confusion.

We feel strongly about the value of early diagnosis that we are innovating over and over again to help deliver it.

Our mission at MARK-B™ platform is to change medical environment by providing affordable and accurate diagnostics in a compact platform designed for use in qualified labs in low volume settings. 

A single,

easy-to-operate platform

Using our proprietary electro-chemistry based technology, we’ve enabled point of care blood testing, so that healthcare professionals can access real-time, lab-quality results within minutes. By putting a lab in their hands, healthcare professionals have the information they need to make treatment decisions sooner, saving precious time. This can help lead to enhanced quality of care for you and your family. 

With these solutions, we continue to impact areas of immediate care, from the intensive care unit to the the emergency room.

OUR HISTORY

2014

Company Found

Oct.  Founded headquarters in Korea

2016 

Aug.   Raised $5 million in 'Series A' round

2018 

Mar.   ‘MARK-B™ cancer’ Clinical testing and joint research with Seoul National University Bundang Hospital

​

Jul.  Presented MARK-B™ Technology at AACC(American Association for Clinical Chemistry) in Chicago, USA​

​

Oct.  Raised 16.5 million in 'Series B'

2020

Jan.  'MARK-B™ analyzer' CE certification, 'MARK-B™ CEA' test cartridge CE certification

​

Jun.  'MARK-B™ COVID-19 Ag S' test cartridge CE certification

​

Jun.  BBB-Celltrion, succeed on joint development of COVID-19 diagnostic kit

​

Oct.  'Celltrion COVID-19 Antigen MIA' FDA EUA anthorization

2015

Jan.  Joined HAX Batch 6 program

​

Apr.  Signed OEM contract with GreenCross MS for supply of in-vitro diagnostic devices for hospitals

​

May.  Tech-In-Asia Award Winner <beGlobal Seoul 2015>

​

Oct.  Winner of Zhongguancun Innoway <2015 Demo The World> in Smart Hardware Sector

2017

Apr.  Signed OEM contract with Philosys Inc. for supply of glucosmeters for hospital use

​

Jun.  Signed MOU with Busan University to commercialize medical research and infrastructure

Jun.  Signed MOU with Korea University Guro Hospital to develop next-generation immunodiagnostic kit for cancer, myocardial infarction, and chronic disease

Aug.  Signed OEM contract with GenBody Inc. for supply of rapid test readers for arboviruses and drugs of abuse

Nov.  Launched elemark® dual check in Korea

2019

Mar.  Completed a Joint “Cancer Diagnostic Performance Verification Clinical Trial” with Seoul National University Bundang Hospital

​

Aug.  Launched elemark® dual check 2 in Korea